| Excerpt | Relevance | Reference |
|---|
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 9.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 5.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |